Literature DB >> 15545519

Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways.

Paolo Calabro1, Ismael Samudio, James T Willerson, Edward T H Yeh.   

Abstract

BACKGROUND: Resistin, a novel adipokine, is elevated in patients with type 2 diabetes and may play a role in the vascular complications of this disorder. One recent study has shown that resistin has a proinflammatory effect on endothelial cells. However, there is no information on whether resistin could also affect vascular smooth muscle cells (SMCs). Thus, the purpose of this study was to assess whether resistin could induce SMC proliferation and to study the mechanisms whereby resistin signals in SMCs. METHODS AND
RESULTS: Human aortic smooth muscle cells (HASMCs) were stimulated with increasing concentrations of resistin for 48 hours. Cell proliferation was induced by resistin in a dose-dependent manner as assessed by direct cell counting. To gain more insights into the mechanism of action of resistin, we investigated the extracellular signal-regulated kinase (ERK) and/or phosphatidylinositol 3-kinase (PI3K) signaling pathways. Transient phosphorylation of the p42/44 mitogen-activated protein kinase (ERK 1/2) occurred after addition of resistin to HASMCs. U0126, a specific inhibitor of ERK phosphorylation, significantly inhibited ERK 1/2 phosphorylation and reduced resistin-simulated proliferation of HASMCs. LY294002, a specific PI3K inhibitor, also significantly inhibited HASMC proliferation after resistin stimulation.
CONCLUSIONS: Our results demonstrate that resistin induces HASMC proliferation through both ERK 1/2 and Akt signaling pathways. The proliferative action exerted by resistin on HASMCs may account in part for the increased incidence of restenosis in diabetes patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15545519     DOI: 10.1161/01.CIR.0000147825.97879.E7

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  80 in total

1.  Adipocyte dysfunction and hypertension.

Authors:  Junlan Zhou; Gangjian Qin
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

2.  Plasma resistin levels associate with risk for hypertension among nondiabetic women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

Review 3.  Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2015-12       Impact factor: 1.894

Review 4.  Adipocyte-derived hormones, cytokines, and mediators.

Authors:  Cristina M Rondinone
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 5.  Human resistin: found in translation from mouse to man.

Authors:  Daniel R Schwartz; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2011-04-15       Impact factor: 12.015

6.  Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20

7.  Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20

8.  PKCε mediates resistin-induced NADPH oxidase activation and inflammation leading to smooth muscle cell dysfunction and intimal hyperplasia.

Authors:  Gayatri Raghuraman; Mary C Zuniga; Hai Yuan; Wei Zhou
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

9.  AKT2 confers protection against aortic aneurysms and dissections.

Authors:  Ying H Shen; Lin Zhang; Pingping Ren; Mary T Nguyen; Sili Zou; Darrell Wu; Xing Li Wang; Joseph S Coselli; Scott A LeMaire
Journal:  Circ Res       Date:  2012-12-18       Impact factor: 17.367

Review 10.  Adipokines and blood pressure control.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Lisa Cassis
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.